DOJ Marijuana Lawsuit Filing Cites Drug Testing Industry And Pharma Company 'Pocketbook Interests' In Opposing Rescheduling

DOJ's Marijuana Rescheduling Court Filing Sends a Dangerous Message

"This case has become much larger than marijuana," Duane Boise CEO of MMJ International Holdings stated. “The government is effectively telling the Court that protecting patients through the FDA approval process and protecting the public through workplace drug testing are…

DOJ Marijuana Lawsuit Filing Cites Drug Testing Industry And Pharma Company 'Pocketbook Interests' In Opposing Rescheduling

The Department of Justice is urging a federal court to reject marijuana opponents’ request to pause the Trump administration’s cannabis rescheduling proposal from moving forward amid overall litigation challenging the reform. The government brief argues that the drug testing industry association and pharmaceutical company seeking to block cannabis rescheduling have “pocketbook interests served by keeping all marijuana in schedule I.” The U.S. Co…

DOJ Says Drug-Testing, Pharma Interests Have Financial Stake in Blocking Marijuana Move to Schedule III

WASHINGTON DC – The U.S. Department of Justice is accusing some of the most vocal opponents of federal marijuana rescheduling of trying to protect their own financial interests rather than public health. In a court filing submitted this week, DOJ attorneys argued that the National Drug and Alcohol Screening Association (NDASA) and MMJ International Holdings, a company developing cannabinoid-based pharmaceuticals, have “pocketbook interests” in p…

Cannabis Rescheduling Brings Tax Relief And Banking Hope To Medical Marijuana Businesses

The federal reclassification of medical marijuana to Schedule III could deliver major tax relief and open banking access for licensed cannabis businesses, with significant implications for South Florida's medical cannabis economy.

DOJ Urges Appeals Court to Reject Attempt to Block Marijuana Rescheduling Order

The Marijuana Herald - Marijuana news and information The U.S. Department of Justice is urging a federal appeals court to reject an attempt to pause an order that moved certain marijuana products from Schedule I to Schedule III under the Controlled Substances Act. In a brief filed Thursday with the U.S. Court of Appeals for the D.C. Circuit, DOJ argued that the challengers “come nowhere near” meeting the standard required for a stay while the ca…

DOJ Marijuana Lawsuit Filing Cites Drug Testing Industry And Pharma Company ‘Pocketbook Interests’ In Opposing Rescheduling

The Department of Justice is urging a federal court to reject marijuana opponents' request to pause the Trump administration's cannabis rescheduling proposal from moving forward amid overall litigation challenging the reform. The government brief argues that the drug testing industry association and pharmaceutical company seeking to block rescheduling have "pocketbook interests served by keeping all marijuana in schedule I." The U.S. Court of Ap…